Something off with this product?
Incorrect prices? Missing information? Delivery time too high?
500+ bought last month
Pentaxim Injection
View Product Details
₹3,024
₹3,550
15% Off
Inclusive of 5% GST
Pack Size
Your Advantages
Delivery By
Enter location
Subtotal :
₹3,024
Want to buy bulk quantity?
Brand: Sanofi
Country of Origin: France
Pentaxim Injection is a pentavalent combination vaccine designed for active immunization against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and invasive infections caused by Haemophilus influenzae type b (Hib). This vaccine is indicated for primary vaccination in infants from two months of age and for booster vaccination during the second year of life.
The vaccine is formulated as a powder and suspension for injection, requiring reconstitution prior to administration. It is administered via the intramuscular route, preferably in the anterolateral side of the thigh for infants and the deltoid area for children.
Key Features :
Provides active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive Haemophilus influenzae type b infections, including meningitis and septicaemia.
Approved for primary vaccination in infants from two months of age and for booster vaccination one year after primary vaccination during the second year of life.
Requires cold-chain storage, maintaining a temperature between 2°C and 8°C, and must not be frozen.
Administered intramuscularly, with recommended injection sites being the anterolateral thigh for infants and the deltoid area for children.
First licensed in Sweden in 1997 and approved by regulatory bodies such as the Ministry of Food and Drug Safety (MFDS) in South Korea and registered in the Russian Federation.
| Antigen Composition | Diphtheria toxoid (≥30 IU), Tetanus toxoid (≥40 IU), Bordetella pertussis antigens (Pertussis toxoid 25 micrograms, Filamentous haemagglutinin 25 micrograms), Inactivated Poliomyelitis virus (Type 1: 29-40 D antigen units, Type 2: 7-8 D antigen units, Type 3: 26-32 D antigen units), Haemophilus influenzae type b polysaccharide (10 micrograms) conjugated with tetanus protein (18-30 micrograms). |
| Approved Indications and Target Population | Joint prevention of diphtheria, tetanus, pertussis, poliomyelitis, and invasive infections caused by Haemophilus influenzae type b (e.g., meningitis, septicaemia, cellulitis, arthritis, epiglottitis). Indicated for primary vaccination in infants from 2 months of age and for booster vaccination one year after primary vaccination during the second year of life. |
| Cold-chain Storage Temperature | Store in a refrigerator between 2°C and 8°C. Do not freeze. |
| Route of Administration | Intramuscular (IM) route. Preferably in the anterolateral side of the thigh (middle third) in infants and in the deltoid area in children. Not for intradermal or intravascular administration. |
| Regulatory Approval | First licensed in Sweden in 1997. Approved by the Ministry of Food and Drug Safety (MFDS) in South Korea on May 9, 2016. Registered in the Russian Federation since 2008. Meets European Union Pharmacopoeia requirements. Marketing Authorization Holder: Sanofi Winthrop Industrie, France. |
| Schedule / Dosing Intervals | Primary immunization typically involves three doses at 1-2 month intervals, starting at 2 months of age (e.g., 2, 3, 4 months or 2, 4, 6 months). A booster dose is recommended one year after primary vaccination, usually between 16 and 18 months of age, or within the second year of life. |
| Reconstitution Requirements | Reconstitute by injecting the suspension of the combined diphtheria, tetanus, acellular pertussis, and poliomyelitis vaccine into the vial containing the Haemophilus type b conjugate vaccine powder. Shake until complete dissolution. The reconstituted suspension is cloudy and whitish. Use immediately after reconstitution. |